Lower circulating BNP levels, often observed in individuals with obesity, may reflect better hemodynamic profiles, which could facilitate improved renal perfusion and enhanced tolerance to HF pharmacotherapies, such as ARNIs, SGLT2 inhibitors, and β-adrenergic receptor blockers (45). This evidence concerns the gene NPPB and obesity disorder.